Kornimate/medical-research-clean huggingface dataset:
fasting versus fed: effect of oral intake prior to the glucose tolerance test in pregnancy

Conditions: Gestational Diabetes; Diagnoses Disease; Pregnancy in Diabetic; Glucose, High Blood

Summary: studies suggest that the timing interval between oral intake and the 1-hour gestational diabetes screen may have a significant impact on gestational diabetes screening glucose levels. the investigators plan to conduct a prospective randomized trial comparing a 6-hour fast versus liberal oral intake within 2 hours prior to the glucose tolerance test in pregnancy in order to evaluate the effect of the fasting versus the fed state on routine gestational diabetes screening results.

gestational diabetes (gdm) complicates approximately 400,000 pregnancies in the united states annually and is associated with significant adverse pregnancy outcomes, including increasing the lifetime risk of type 2 diabetes. the american college of obstetricians and gynecologists (acog) recommends that all pregnant women undergo gdm screening between 24-28 weeks gestation utilizing a 1-hour oral glucose tolerance test that was designed to be administered without regard to the last meal or time of day. however, studies suggest that the timing of one's last meal prior to the 1-hour gdm screen may have a significant impact on gdm screening glucose levels. in addition, providers routinely alter the timing of the 1-hour gdm screen based on patients' self reported oral intake prior to the exam. the investigators plan to conduct a prospective randomized trial comparing a 6-hour fast versus liberal oral intake within 2 hours prior to the glucose tolerance test in pregnancy in order to evaluate the effect of the fasting versus the fed state on routine gdm screening results.

Eligibility criteria:
inclusion criteria: 1. pregnant patients 18 years and older 2. singleton gestation 3. pregnancy managed at lucile packard children's hospital (lpch) stanford outpatient obstetrics clinic 4. planned delivery at lucile packard children's hospital (lpch) stanford labor and delivery unit exclusion criteria: 1. pregestational diabetes 2. gestational diabetes diagnosed in the 1st trimester 3. less than 18 years of age 4. planned delivery outside lpch 5. diabetes medication use prior to pregnancy 6. inability to give informed consent 7. chronic steroid use in pregnancy 8. less than 24 weeks of gestation at the time of the 1 hour oral glucose tolerance test 9. prior history of bariatric surgery 10. multifetal gestation
a usability study of external neuromodulation with itear100 generation 2

Conditions: Dry Eye Syndromes

Summary: a usability study of external neuromodulation with itear100 generation 2. a study which evaluates user ability to train and access the itear100 device in a telehealth environment.

a usability study of external neuromodulation with itear100 generation 2. a study which evaluates user ability to train and access the itear100 device in a telehealth environment. subjects sign a consent form and are sent a device. after downloading a mobile app, they can access the device and download a prescription. at 7 days, an official telehealth visit evaluates their success in the set up and training. at 30 days, the trial ends, a usability survey and symptom evaluation survey are used to determine success.

Eligibility criteria:
inclusion criteria: able to sign english language consent form and over age 18 and reside in the u.s. - exclusion criteria: -
investigation to evaluate the efficacy and safety of exufiber versus aquacel extra in moderately or strongly exuding venous and mixed ulcers of predominantly venous origin

Conditions: Venous Leg Ulcer

Summary: the investigation is designed as an open, randomized, non-inferiority, multi-centre investigation. 212 evaluable subjects will be randomised. subjects to be included will suffer from an exuding venous or mixed ulcer of predominantly venous origin. subjects will either be randomized to exufiber®gelling fibre dressing or aquacel®extra hydrofiber® dressing with strengthening fibre using, centralized randomization

visits are planned for baseline followed by 1, 2, 3, 4 and 6 weeks post treatment. the sub-group of at least 50 subjects will also be followed at week 8, 12, 16, 20, and 24 post treatment or until wound is healed if earlier.

Eligibility criteria:
inclusion criteria: 1. provision of informed consent i.e. subject must be able to understand and sign the patient information and consent form 2. both gender ≥18 years old 3. ulcer moderately or strongly exudative justifying the use of an absorbent dressing 4. (history of compression at least two weeks before inclusion) deleted in am.2 5. (wound covered with slough ≥70%) deleted in am.4 6. 0.7≤abpi\<1.3 7. ulcer duration 6 weeks to 60 months 8. ulcer size 3 cm2-100 cm2 9. target ulcer at least 3 cm away from any other lesion exclusion criteria: 1. known allergy/hypersensitivity to the dressings 2. pregnant or breastfeeding 3. circumferential wounds (the entire wound should be able to be captured on a single image/photo) 4. subjects who will have problems following the protocol 5. subjects included in other ongoing clinical investigation evaluating wound dressings at present or during the past 30 days 6. patient with a systemic infection not controlled by suitable antibiotic treatment 7. clinically infected wound according to the judgement of the investigator (heat, pain, swelling, redness or purulent secretion) 8. wound covered with black necrosis 9. dry wounds 10. malignant wound degeneration 11. current treatment with radiotherapy, chemotherapy, immunosuppressant drugs or high doses of oral corticosteroids if any 12. subject with deep vein thrombosis within 3 months prior to inclusion

Keywords: wound reduction wound healing, venous ulcers
corn occupational rhinitis scit efficacy study

Conditions: Rhinitis

Summary: patients demonstrated allergic to corn pollen and timothy grass pollen (by allergy testing) who have undergone 1 to 2 years of subcutaneous allergen immunotherapy (scit) containing timothy grass extract with moderate symptomology (as documented via rhinitis symptom score surveys) will constitute the treatment group. those who previously chose not to undergo scit who have documented symptomology and are skin test positive to corn pollen will constitute the control group. prospective symptom score analyses and retrospective quality of life assessments (rqlq) will be the primary and secondary efficacy outcome measures.

statistical assessment suggests enrollment of 20 patients into the treatment group (defined above) and an additional 20 into the control group. patients will be matched for the level of symptomology (based on symptom score surveys) and residing/working on corn-crop farms. the premise for this study is the cross-reactivity of putative immunogenic sites between timothy grass pollen and corn pollen. based on consensus genetic sequences. thus, the hypothesis is the use of timothy grass extract containing immunotherapy would diminish symptomology to corn-based occupational rhinitis. enrolled patients will have signed irb approved consent forms and have undergone scit for 1 to 2 plus years (treatment group) or not undergone scit therapy for the same time period (control group). potential contribution to symptom scores from other sources (e.g. ragweed) will be analyzed by assessment of local pollen counts.efficacy assessment will compare prospective symptom score results and retrospective quality of life survey scores between the treatment and control group responses.

Eligibility criteria:
inclusion criteria for treatment group: 1. completing more than 1 year of timothy grass scit 2. residing/working on/near a corn farm 3. having an initial symptom score value of \> 8 (out of a possible 21). inclusion criteria for control group: 1. never treated with scit. 2. residing/working on/near a corn farm 3. having an initial symptom score value of \> 8 (out of a possible 21). all accepted enrolled patients are healthy volunteers. exclusion criteria: 1. negative allergy test to corn pollen, 2. not residing on/near farm growing corn, 3. an initial symptom score of \< 9.
clinical evaluation of 68ga-nota-mal-cys39-exendin-4 positron emission tomography in the detection of insulinoma

Conditions: Insulinoma

Summary: glucagon-like peptide-1 receptor (glp-1r) is a kind of g protein coupled receptor which regulate the insulin secretion and serves as potential target in the diagnosis of functional pancreas neuroendocrine tumor. the aim of this study was the clinical evaluation of a potential glp-1r targeted tracer 68ga-nota-mal-cys39-exendin-4 for the detection of insulinoma.

since glp-1r is expressed in human β-cells and highly overexpressed in insulinomas，multiple glp-1r-targeted radiopharmaceuticals were devoted to insulinoma localization imaging.68ga-nota-mal-cys39-exendin-4 is an optimal probe targeting glp-1r. a single dose of 111-185 mega-becquerel (mbq) 68ga-nota-mal-cys39-exendin-4 will be injected intravenously. visual and semiquantitative method will be used to assess the pet/ct images.the investigators will determine the use of 68ga-nota-mal-cys39-exendin-4 pet/ct in the detection of insulinomas, and to compare its diagnostic value with conventional imaging.

Eligibility criteria:
inclusion criteria: 1. the patient volunteers and signs an informed consent form. 2. age ≥18 and ≤75 years old; 3. patients with hypoglycaemia in the presence of neuroglycopenic symptoms and documented whipple's triad; 4. biochemically proven endogenous hyperinsulinemic hypoglycaemia (plasma glucose concentration \ 3 µu/ml, and c-peptide \>0.6 ng/ml); 5. conventional imaging within 3 month. exclusion criteria: 1. having a history of allergy to similar drugs, allergic constitution or suffering from allergic diseases; 2. breast feeding; 3. pregnancy or the wish to become pregnant within 6 months; 4. renal function: serum creatinine \> 3.0 mg/dl; 5. any medical condition that, in the opinion of the investigator, may significantly interfere with study compliance.
prognostic contribution of abdominal ultrasound in necrotizing enterocolitis in preterm infants less than 33sa.

Conditions: the Necrotizing Enterocolitis; Preterm Infants

Summary: enterocolitis necrotizing (ecun) is a common and serious gastrointestinal disease in premature infants. the diagnosis of ecun based on clinical and radiological criteria. the abdomen plain film to date is the reference examination to confirm or refute the diagnosis. indeed, the presence of pathognomonic signs (pneumatosis, aéroportie) on the abdomen of cliché can confirm the diagnosis. the prognostic value of these radiographic findings is currently controversial. abdominal ultrasound is a test whose possibilities in diagnostic and prognostic term began to be considered for some years. it also has other advantages, including that of not being a radiating examination. studies on the prognostic value of abdominal ultrasound are rather few. moreover, they involve a series of heterogeneous patients in terms of gestational age. or the pathophysiology of ecun in children born at term and in children born prematurely is not the same. the objective is to study prospectively the prognostic contribution of abdominal ultrasound in the ecun in premature under 33sa.


Eligibility criteria:
inclusion criteria: * birth term strictly less than 33sa * gestational age some (assessed on early ultrasound dating) * congenital malformation of absence * suggestive clinical symptomatology of ecun defined by the presence of abdominal bloating, increased residues (\> 20% of the volume of enteral feeding) and the presence of blood in stool (macro- or microscopic) * radiologic investigation with a radiograph of abdomen and abdominal ultrasound done for the episode of ecun * maximum interval between imaging tests 2 hours * no parental opposition to the participation of children in the study exclusion criteria: * term higher or equal to 33 weeks * congenital malformation * parental opposition (or legal representatives) to participate in the study
mulligan's mobilization and proprioceptive neuromuscular facilitation technique in sacroiliac joint dysfunction

Conditions: SACROILIAC JOINT DYSFUNCTION

Summary: this study will aim to compare the effects of mulligan mobilization and pnf on pain and disability with patients of sij dysfunction and will be helpful for clinical physiotherapist to choose more effective treatment protocol for patients as there are fewer researches on comparison of these techniques.

the sacroiliac joint dysfunction syndrome (sijds) is an ongoing controversial issue and an important source of low back pain (lbp). it has been emphasized in many studies that the pathologies of sacroiliac joint (sij) are a source of pain in the lumbar spine and hip region. the prevalence of sijds in patients with chronic mechanical lbp is between 15 and 30% sijd is a condition in which pain arises from the sacroiliac joint and is caused by the abnormal movement of ilium around the sacrum and abnormal function of the sij structures, like ligaments, muscles, capsules. the prevalence of sijp has been stated to be up to 75% in lbp patients. physiotherapy techniques are used to correct sij mal-alignment manually by restoring the normal function and balance of lumbar and pelvic muscles and ligaments. mulligan described the positional fault theory in which articular mal-alignment leads to altered kinematics and eventual dysfunction(2). proprioceptive neuromuscular facilitation (pnf) is a form of flexibility exercises used to resolve muscle shortening and strain.

Eligibility criteria:
inclusion criteria: * age 20 to 35 years * both genders * subjects with positive provocation test ( faber's test\\patricks test, gaenslen test, distraction test, compression test, sacral thrust test) * subjects with positive innominate test ( stork test\\gillet test) * subjects who agree to fill the informed consent exclusion criteria: * pregnant women * presence of neurological signs * patient with ankylosis spondylosis. * patient has been diagnosed by disease other than sij dysfunction * patients having any congenital posture problem or previous surgery * slr less than 45 degree * patient having any mental problem or reduced cognitive ability

Keywords: mulligan mobilization proprioceptive neuromuscular facilitation contract relax sacroiliac joint dysfunction
diagnostic accuracy of cfd-based fractional flow reserve derived from coronary angiography

Conditions: Coronary Artery Disease

Summary: this is a prospective, multicenter, self-control clinical trial designed to assess the efficacy of accuffrangio, a novel method for evaluating the functional significance of coronary stenosis from coronary angiography, with ffr as the reference standard.


Eligibility criteria:
inclusion criteria: * age ≥18 years; * stable or unstable angina, or myocardial infarction after the acute phase, indication for ffr in at least one vessel; * able to provide informed consent. exclusion criteria: * subjects judged unsuitable for diagnostic intervention or ffr; * myocardial infarction within 6 days; * lvef ≤50%; * egfr \<60ml/min（1.73m²） * severe coagulation dysfunction or bleeding disorders; * allergic to iodine contrast agent or adenosine, or ineligible for adenosine; * participated in other clinical trials within 1 months; * other situations that were not suitable for inclusion, as judged by investigators.
internet-delivered cognitive behavioural therapy in arabic for anxiety and depression

Conditions: Anxiety; Depression

Summary: the purpose of this study is to evaluate the efficacy of a culturally adapted internet-administrated cognitive behaviour therapy (icbt) in arabic for anxiety and depression

the study will compare the effect of the intervention against a wait-list control. the intervention tested is based on cognitive behavior therapy delivered over the internet via a secure treatment platform. participants in the study are recruited from the general public via social media. the intervention is in arabic.

Eligibility criteria:
inclusion criteria: * be above 18 years of age * have symptoms of anxiety and/or depression * be able to read and write in arabic * have access to computer or smartphone exclusion criteria: * suicidal ideation * alcohol addiction * other major primary psychiatric disorder * ongoing psychological treatment * recent (during last 4 weeks) change in psychiatric medication
vitamin d and pregnancy outcome in pcos patients

Conditions: Polycystic Ovary Syndrome; in Vitro Fertilization

Summary: this multicenter double-blinded placebo-controlled randomised trial aims to evaluate the effectiveness of vitamin d supplementation prior to ivf on the live birth rate in women with pcos. women with pcos scheduled for ivf will be enrolled. eligible participants will be randomised 1:1 to receive oral capsules of 4000iu vitamin d per day or placebo for around 12 weeks until the day of triggering.

polycystic ovary syndrome (pcos) is one of the leading causes of female infertility, affecting around 5% of women with a child-bearing age in china. vitamin d insufficiency is common in women with pcos and is associated with lower live birth rates in these women. however, evidence regarding the effectiveness of vitamin d treatment in women with pcos is inconclusive. this multicenter double-blinded placebo-controlled randomised trial aims to evaluate the effectiveness of vitamin d supplementation prior to ivf on the live birth rate in women with pcos. the investigators plan to enroll women with pcos scheduled for ivf. eligible participants will be randomised 1:1 to receive oral capsules of 4000iu vitamin d per day or placebo for around 12 weeks until the day of triggering. all ivf procedures will be carried out following a routine method in each center. women will be followed up until six months after randomisation for those who fail to get pregnant after the completion of the first embryo transfer or delivery for those who get pregnant after the first embryo transfer. the primary outcome is live birth after the first embryo transfer. primary analysis will be by intention-to-treat analysis. the investigators plan to recruit 860 women to demonstrate women treated with vitamin d have a higher live birth rate than those treated with placebo (48% versus 38%), accounting for 10% loss to follow-up with a significance level at 0.05 and a power of 80%.

Eligibility criteria:
inclusion criteria 1. women aged 20 to 42 years old; 2. diagnosed with pcos (rotterdam criteria); 3. scheduled for ivf; 4. written informed consent. exclusion criteria 1. women who had three or more failed ivf cycles; 2. women scheduled for preimplantation genetic testing; 3. known vitamin d allergy; 4. women with a history of chronic absorption syndrome or bile dysplasia, or parathyroid dysfunction, or kidney stones, or blood calcium ion concentration greater than 2.6mmol/l (normal value 2.25 - 2.75mmol/l (9 to 11mg/dl), or hyperphosphataemia (1.61mmol/l), or metabolic-related bone disease, or chronic diseases that may cause bone abnormalities (liver and kidney insufficiency); 5. women receiving treatments for tuberculosis, convulsions, and epilepsy because medications treating these diseases may affect the metabolism of vitamin d. 6. women undergoing an ivf treatment with donor oocytes.

Keywords: polycystic ovary syndrome in vitro fertilization vitamin d randomized trial
a research study to understand how people with type 2 diabetes take ozempic® and if the ozempic®app helps them stay on this treatment

Conditions: Diabetes Mellitus, Type 2

Summary: this study looks at how participants with type 2 diabetes take ozempic® and if the ozempic® app helps participants to stay on this treatment. participants will already be prescribed with ozempic® by the study doctor. participants may be asked to use a device called mallya®, which participants must attach to their ozempic® injection pen. participants might also be asked to install an ozempic® app on their mobile phone which supports the participants in the use of ozempic®. at the beginning and at the end of this study, the participants will have to fill out some questionnaires about their diabetes treatment. participants may also be chosen to participate in a voluntary non-mandatory interview after the study has ended. the total duration of study is approximately 10 months.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * the decision to initiate treatment with commercially available semaglutide s.c. has been made by the patient and the health care providers (hcp) and independently from the decision to include the patient in this study. patients can be randomised up to 10 days after being prescribed semaglutide. * treatment with semaglutide s.c. is needed for intensification of glycaemic control and used according to label as judged by hcp. * male or female; aged 25-75 years (both inclusive) at the time of signing informed consent. * diagnosed with type 2 diabetes (t2d) at least 180 days prior to obtaining informed consent. * willing to comply with the protocol requirements which includes use of patient support solution (pss) app on own mobile device (iphone operating system (ios) 11 (or higher) and android 4.1 (or higher) devices), using mallya®, filling out questionnaires as judged by the hcp. exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study. * treatment with any investigational drug within 30 days prior to enrolment into the study. * glucagon like peptide-1 receptor agonist (glp-1 ra) use for 90 days prior to randomisation. however, one prescription of once-weekly semaglutide subcutaneously (s.c.) is allowed up to 10 days prior to randomisation. * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * use of pacemaker or body worn infusion pumps according to mallya®'s instruction for use. * impaired eyesight prohibiting readability of pss app provided on mobile device. * inability to independently self-manage anti-diabetic treatments received as judged by hcp. * inability to independently inject semaglutide s.c. treatment as judged by hcp. * inability to fulfil study requirement as judged by the hcp.